Cartesian Therapeutics (RNAC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cartesian Therapeutics (RNAC) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.33 of bullish evidence against -0.35 bearish.

Cartesian Therapeutics last closed at $7.14, -2.99% on the session.

Against the IVW growth benchmark the position is -3.91% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

15 graded predictions for RNAC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cartesian Therapeutics in the 97th percentile on return on equity, where 100 is best.

Cartesian Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $222.68M.

StockMap tracks Cartesian Therapeutics as the 220th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Cartesian Therapeutics ranks 275th of 344 in the group, against a group median of -0.21.